{"nctId":"NCT00509262","briefTitle":"Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)","startDateStruct":{"date":"2007-10-09","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2","Renal Insufficiency, Chronic"],"count":426,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin","Drug: Placebo for Glipizide"]},{"label":"Glipizide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Glipizide","Drug: Placebo for Sitagliptin"]}],"interventions":[{"name":"Sitagliptin","otherNames":["MK-0431","Januvia"]},{"name":"Glipizide","otherNames":["Glucotrol"]},{"name":"Placebo for Sitagliptin","otherNames":[]},{"name":"Placebo for Glipizide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has type 2 diabetes mellitus\n* Has moderate or severe renal insufficiency\n\nExclusion Criteria:\n\n* Has type 1 diabetes mellitus or a history of ketoacidosis\n* Is on a new weight loss program\n* Has active liver disease\n* Is on dialysis or is likely to need dialysis during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C) Levels at Week 54","description":"A1C represents percentage of glycosylated hemoglobin.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.76","spread":"0.65"},{"groupId":"OG001","value":"7.79","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.70","spread":"0.80"},{"groupId":"OG001","value":"-0.62","spread":"0.91"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Hypoglycemic Events","description":"Percentage of participants with at least one symptomatic hypoglycemic adverse event, excluding data after initiation of glycemic rescue therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"17.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 54","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148.6","spread":"39.9"},{"groupId":"OG001","value":"143.9","spread":"35.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.7","spread":"47.1"},{"groupId":"OG001","value":"-20.2","spread":"48.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 54","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.3"},{"groupId":"OG001","value":"1.2","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":210},"commonTop":["Blood glucose decreased","Hypoglycaemia","Urinary tract infection","Oedema peripheral","Upper respiratory tract infection"]}}}